PRAMOMOLECULAR
PRAMOMOLECULAR is dedicated to developing innovative gene silencing therapies using self-delivering siRNAs. Their mission is to provide effective and well-tolerated therapeutics for serious diseases, including cancer and heart failure, by leveraging proprietary platform technology for nucleic acid-based drugs. They aim to address currently incurable diseases and collaborate with other developers through co-development and licensing of their delivery technology.
Industries
Nr. of Employees
small (1-50)
PRAMOMOLECULAR
Robert-Rössle-Strasse 10, 13125 Berlin, Building D79 / 1st Floor
Products
Self-delivering siRNA drug candidates (pipeline)
A pipeline of siRNA-based therapeutic candidates formulated with lipid-conjugated delivery molecules designed to downregulate mutated or overexpressed proteins; intended indications include KRAS-dependent cancers and heart failure.
Self-delivering siRNA drug candidates (pipeline)
A pipeline of siRNA-based therapeutic candidates formulated with lipid-conjugated delivery molecules designed to downregulate mutated or overexpressed proteins; intended indications include KRAS-dependent cancers and heart failure.
Services
Partnership-based co-development and licensing of delivery chemistries and formulations for nucleic acid-based drugs.
Design and execution of in vivo proof-of-concept studies in mouse PDX models to evaluate efficacy of nucleic acid therapeutic candidates against oncogenic targets.
Partnership-based co-development and licensing of delivery chemistries and formulations for nucleic acid-based drugs.
Design and execution of in vivo proof-of-concept studies in mouse PDX models to evaluate efficacy of nucleic acid therapeutic candidates against oncogenic targets.
Expertise Areas
- siRNA therapeutics and gene silencing
- Nucleic acid delivery chemistry and formulation
- Preclinical oncology models and in vivo efficacy studies
- Tissue-targeted delivery to lung, heart and pancreas
Key Technologies
- siRNA-mediated gene silencing
- Lipid-conjugated delivery molecules for nucleic acids
- Patient-derived xenograft (PDX) mouse models
- Systemic, intraperitoneal and local administration of therapeutics
News & Updates
An article about a professional journey, linked to the company's news coverage.
An article about a device or method to open doors against cancer, featured in the company's news.
An article discussing innovative drug development for difficult diseases.
An article about advancements in siRNA targeting and delivery technologies.
A ranking article featuring PRAMO among top drug development companies.
An article about PRAMO winning an innovation award.
An article about a professional journey, linked to the company's news coverage.
An article about a device or method to open doors against cancer, featured in the company's news.
An article discussing innovative drug development for difficult diseases.
An article about advancements in siRNA targeting and delivery technologies.
A ranking article featuring PRAMO among top drug development companies.
An article about PRAMO winning an innovation award.